Rajesh (Raj) Devraj, Ph.D., is President and Chief Executive Officer of Rectify and a Venture Partner at Atlas Venture. Throughout his career, he has been focused on creating and building groundbreaking biotech companies. Prior to Rectify, Raj co-founded Disarm Therapeutics with Atlas and served as its Chief Scientific Officer prior to its acquisition. Before Disarm, he served as Chief Scientific Officer of Atlas-founded Padlock Therapeutics. Prior to his tenure at Atlas, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. In addition, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj also serves on the boards of directors for several biotech companies. Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his B.S. in Pharmacy from University of Mumbai, and Ph.D. in Medicinal Chemistry from Duquesne University.
Rectifying function, restoring hope
Developing disease-modifying precision therapeutics for patients with serious genetic diseases
Rectify is developing Positive Functional Modulators (PFMs), disease-modifying precision therapeutics that restore ABC transporter function for patients with serious genetic diseases.
ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system.
Scientific Advisory Board
Richard Thompson BM BCh, DM
Professor of Molecular Hepatology, School of Immunology & Microbial Sciences at King’s College London
Jamie Williamson Ph.D.
Professor, Department of Integrative Structural and Computational Biology, Scripps Research Institute